The Upcoming PCAC Meeting The FDA notice confirms that the PCAC will convene this summer to evaluate whether to recommend the following seven bulk drug substances for inclusion on the 503A bulks list: July 23, 2026: BPC-157 (free base / acetate) KPV (free base / acetate) Thymosin Beta-4, Fragment (LKKTETQ) (TB-500) (free base / acetate) MOTs-C (free base / acetate) July 24, 2026: Emideltide (DSIP) (free base / acetate) Semax (free base / acetate) Epitalon (free base / acetate) All seven substances are of considerable interest to compounding pharmacies, prescribers, and patients
NAD+ accumulates, signaling fat cells to enter a fat-burning state over weeks of consistent use
Potential tumor promotion : Given its angiogenic properties, there is theoretical concern it could contribute to tumor growth or neovascularization in certain contexts
In keratosis pilaris, you get rough, dry patches and small bumps generally on your upper arms, buttocks, thighs, or sometimes cheeks
Honest about evidence: IV hydration and repleting a real deficiency are well established, while broad claims that drips cure illness or reverse aging are not, so we use IV therapy for specific, realistic goals
.png)
